Scarica l'app Stockscreener
18.80
2.08%
-0.40
Pre-mercato:
18.77
-0.03
-0.16%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SDGR Giù?
Forum
Previsione
Precedente Chiudi:
$19.20
Aprire:
$18.81
Volume 24 ore:
510.73K
Relative Volume:
0.45
Capitalizzazione di mercato:
$1.41B
Reddito:
$254.91M
Utile/perdita netta:
$-103.48M
Rapporto P/E:
-13.39
EPS:
-1.4036
Flusso di cassa netto:
$-148.35M
1 W Prestazione:
-9.22%
1M Prestazione:
+0.16%
6M Prestazione:
+48.85%
1 anno Prestazione:
+3.58%
Intervallo 1D:
$18.69
$19.20
Intervallo di 1 settimana:
$18.69
$20.67
Portata 52W:
$10.95
$23.02
Schrodinger Inc Stock (SDGR) Company Profile
Nome
Schrodinger Inc
Settore
Industria
Telefono
503-299-1150
Indirizzo
1540 BROADWAY, NEW YORK, NY
Compare SDGR vs VEEV, BTSG, TEM, TXG, HQY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SDGR
Schrodinger Inc
|
18.80 | 1.41B | 254.91M | -103.48M | -148.35M | -1.4036 |
VEEV
Veeva Systems Inc
|
260.98 | 42.25B | 3.32B | 941.65M | 1.64B | 5.6161 |
BTSG
Brightspring Health Services Inc
|
57.88 | 11.45B | 13.65B | 169.86M | 412.12M | 1.0758 |
TEM
Tempus Ai Inc
|
58.74 | 10.66B | 1.36B | -302.91M | -219.93M | -1.7182 |
TXG
10 X Genomics Inc
|
66.38 | 8.65B | 638.78M | -22.66M | 122.18M | -0.1744 |
HQY
Healthequity Inc
|
94.55 | 7.82B | 1.34B | 230.70M | 440.96M | 2.6695 |
Schrodinger Inc Stock (SDGR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-15 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-09-30 | Iniziato | Goldman | Neutral |
| 2025-08-15 | Downgrade | Citigroup | Buy → Neutral |
| 2025-08-14 | Iniziato | Barclays | Overweight |
| 2025-07-03 | Ripresa | Morgan Stanley | Equal-Weight |
| 2024-07-02 | Iniziato | Leerink Partners | Outperform |
| 2023-12-05 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2023-05-05 | Ripresa | Piper Sandler | Overweight |
| 2022-12-19 | Iniziato | Goldman | Neutral |
| 2022-03-01 | Iniziato | Citigroup | Buy |
| 2021-11-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-19 | Iniziato | Piper Sandler | Overweight |
| 2021-11-11 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-10-13 | Iniziato | Berenberg | Buy |
| 2021-09-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-05-25 | Iniziato | Craig Hallum | Buy |
| 2020-11-23 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2020-10-12 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-03-02 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-02 | Iniziato | Jefferies | Hold |
| 2020-03-02 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Schrodinger Inc Borsa (SDGR) Ultime notizie
Schrödinger introduces Tectora Therapeutics - BioWorld News
Tectora Therapeutics inc. announced that it has received $55 million in funding from New Enterprise Associates, Inc., RA Capital Management, L.P., Schrödinger, Inc. - marketscreener.com
Schrödinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics, a New Biotechnology Company It Co-founded to Advance Immunology and Inflammation Programs - BioSpace
SDGR Looks 19.2% Undervalued on GF Value™ - GuruFocus
Schrodinger Establishes Tectora Therapeutics With RA Capital, New Enterprise Associates - marketscreener.com
A new drug company raises $55 million for oral medicines - Stock Titan
Is Schrodinger Inc (SDGR) a Bargain After 3.1% Drop? GF Value Sa - GuruFocus
Schrodinger (SDGR) Slips 1.3% as Shares Hold Above Key $19.58 SupportPut Flow Alert - dars.gov.et
Can RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook? - TradingView
“Schrodinger’s Strait:” Why Hormuz Now Exists in a State of Permanent Uncertainty - Yahoo Finance
AI in Drug Discovery Market Projected to Reach $8.52 Billion By 2030 - PR Newswire
Schrödinger’s Strait - الحرة
Price-Driven Insight from (SDGR) for Rule-Based Strategy - Stock Traders Daily
Drug Discovery Platforms Market to Reach USD 16.5 Billion by 2036, Driven by AI-Powered Research and Rising Pharmaceutical R&D Investment - industrytoday.co.uk
Schrödinger to Present at Morgan Stanley Global Healthcare Conference 2026 - BioSpace
Schrödinger to Present at Morgan Stanley Global Healthcare Conference - Yahoo Finance
Schrodinger Inc. (SDGR) Slips 1.81% to $20.04 as Stock Holds Above Key SupportInsider Selling Alerts - dars.gov.et
SDGR | Schrodinger, Inc. Common Stock FinancialsRevenue Breakdown - Quiver Quantitative
Schrödinger: The Software Business Is Stronger Than It Looks (NASDAQ:SDGR) - Seeking Alpha
Schrödinger (SDGR) Q2 2026 Earnings Call Transcript - AOL.com
Tejara Capital Ltd Takes $4.55 Million Position in Schrodinger, Inc. $SDGR - MarketBeat
Schrodinger (NASDAQ:SDGR) Trading 10.4% HigherWhat's Next? - MarketBeat
BMO Capital Maintains Schrodinger(SDGR.US) With Buy Rating, Maintains Target Price $24 - Moomoo
Schrodinger Inc (SDGR) News, Articles, Events & Latest Updates - Stocktwits
The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci - Zacks Investment Research
Schrödinger-BMS collaboration centers on Bunsen for trillion-scale computational drug discovery - drugdiscoverytrends.com
Schrodinger Inc. (SDGR) Slides 4.7% to $17.59 as Bearish Momentum BuildsCounter Trend Trade - Vinanet
SDGR Looks 29.7% Undervalued on GF Value™ - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
Schrodinger (SDGR) Slides 4.7% to $17.59 as Selling Pressure MountsSynthetic Short - Vinanet
Schrodinger Inc (SDGR) Stock Down 4.8% -- Now Undervalued? GF Sc - GuruFocus
UBS initiates Schrodinger stock coverage with neutral rating By Investing.com - Investing.com South Africa
SDGR Assumed by UBS -- Price Target Raised to $19.00 - GuruFocus
UBS Maintains Schrodinger(SDGR.US) With Hold Rating, Maintains Target Price $19 - Moomoo
Schrodinger Coverage Assumed by UBS at Neutral - Moomoo
UBS Adjusts Schrodinger PT to $19 From $13, Maintains Neutral Rating - marketscreener.com
Schrödinger Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Two New Schrödinger Hires Get Stock Awards Vesting Over Four Years - Stock Titan
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
UBS initiates Schrodinger stock coverage with neutral rating - Investing.com Nigeria
UBS Initiates Schrodinger(SDGR.US) With Hold Rating, Announces Target Price $19 - Moomoo
Schrodinger, Inc. Stock 12‑Month Price Target Raised to $21.83, Implies 18% Upside - TradingView
Analysts’ Opinions Are Mixed on These Healthcare Stocks: AIM ImmunoTech (AIM) and Schrodinger (SDGR) - The Globe and Mail
Schrodinger, Inc. (SDGR) Stock Forecasts - Yahoo! Finance Canada
Technical Reactions to SDGR Trends in Macro Strategies - Stock Traders Daily
Quantinno Capital Management LP Buys Shares of 174,095 Schrodinger, Inc. $SDGR - MarketBeat
Schrödinger (SDGR) Is Up 19.2% After AI Pact With BMS And Q2 ProfitabilityHas The Bull Case Changed? - simplywall.st
Schrödinger Unveils Bunsen, an AI Co-Scientist for Enhanced Molecular Discovery - SynBioBeta
SDGR Q2 2026 Earnings: EPS of $0.08 Beats Estimates with a 116.27% SurpriseReturn On Capital - vinanet.vn
Dimensional Fund Advisors LP Cuts Holdings in Schrodinger, Inc. $SDGR - MarketBeat
Results: Schrödinger, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - webull.com
Schrodinger Inc Azioni (SDGR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.53%
2.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):